Drug testing in the patient: Toward personalized cancer treatment

Science Translational Medicine

Volumn 7, Issue 284, 2015, Pages 284re3-

  Coombes, R Charles ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTICLE; BIOENGINEERING; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; DRUG USE; HUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; DEVICES; DRUG MONITORING; LYMPHOMA; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG MONITORING; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LYMPHOMA; NEOPLASMS;

EID: 84928683208     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aab1214     Document Type: Article

References (10)

1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J. W. Coebergh, H. Comber, D. Forman, F. Bray, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374-1403 (2013).
2. O. Jonas, H. M. Landry, J. E. Fuller, J. T. Santini Jr., J. Baselga, R. I. Tepper, M. J. Cima, R. Langer, An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci. Transl. Med. 7, 284ra57 (2015).
3. R. A. Klinghoffer, S. B. Bahrami, B. A. Hatton, J. P. Frazier, A. Moreno-Gonzalez, A. D. Strand, W. S. Kerwin, J. R. Casalini, D. J. Thirstrup, S. You, S. M. Morris, K. L. Watts, M. Veiseh, M. O. Grenley, I. Tretyak, J. Dey, M. Carleton, E. Beirne, K. D. Pedro, S. H. Ditzler, E. J. Girard, T. L. Deckwerth, J. A. Bertout, K. A. Meleo, E. H. Filvaroff, R. Chopra, O. W. Press, J. M. Olson, A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci. Transl. Med. 7, 284ra58 (2015).
4. C. Holohan, S. Van Schaeybroeck, D. B. Longley, P. G. Johnston, Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
5. P. Eirew, A. Steif, J. Khattra, G. Ha, D. Yap, H. Farahani, K. Gelmon, S. Chia, C. Mar, A. Wan, E. Laks, J. Biele, K. Shumansky, J. Rosner, A. McPherson, C. Nielsen, A. J. Roth, C. Lefebvre, A. Bashashati, C. de Souza, C. Siu, R. Aniba, J. Brimhall, A. Oloumi, T. Osako, A. Bruna, J. L. Sandoval, T. Algara, W. Greenwood, K. Leung, H. Cheng, H. Xue, Y. Wang, D. Lin, A. J. Mungall, R. Moore, Y. Zhao, J. Lorette, L. Nguyen, D. Huntsman, C. J. Eaves, C. Hansen, M. A. Marra, C. Caldas, S. P. Shah, S. Aparicio, Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422-426 (2015).
6. K. J. Patel, O. Trédan, I. F. Tannock, Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother. Pharmacol. 72, 127-138 (2013).
7. C. Swanton, Cancer evolution constrained by mutation order. N. Engl. J. Med. 372, 661-663 (2015).
8. P. A. Netti, D. A. Berk, M. A. Swartz, A. J. Grodzinsky, R. K. Jain, Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497-2503 (2000).
9. T. Fukamachi, Y. Chiba, X. Wang, H. Saito, M. Tagawa, H. Kobayashi, Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin. Cancer Lett. 297, 182-189 (2010).
10. B. Majumder, U. Baraneedharan, S. Thiyagarajan, P. Radhakrishnan, H. Narasimhan, M. Dhandapani, N. Brijwani, D. D. Pinto, A. Prasath, B. U. Shanthappa, A. Thayakumar, R. Surendran, G. K. Babu, A. M. Shenoy, M. A. Kuriakose, G. Bergthold, P. Horowitz, M. Loda, R. Beroukhim, S. Agarwal, S. Sengupta, M. Sundaram, P. K. Majumder, Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat. Commun. 6, 6169 (2015).